3-甲基-反-1,2-环丙烷二羧酸甲酯 | 28363-79-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-甲基-反-1,2-环丙烷二羧酸甲酯
• 英文名称: methyl 3-methylcyclopropane-1α,2β-dicarboxylate
• 英文别名: (+/-)-3-methyl-cyclopropane-dicarboxylic acid-(1r.2t)-dimethyl ester；(+/-)-3-Methyl-cyclopropan-dicarbonsaeure-(1r.2t)-dimethylester；dimethyl (1R,2R)-3-methylcyclopropane-1,2-dicarboxylate
• CAS: 28363-79-3
• 化学式: C₈H₁₂O₄
• 分子量: 172.181
• InChiKey: RXDPFIPAMAIMFJ-PHDIDXHHSA-N

物化性质

• 沸点：
  100 °C (18 mmHg)
• 密度：
  1.2104 (rough estimate)
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险类别码：
  R24/25
• 海关编码：
  2917209090
• 储存条件：
  存于阴凉干燥处

SDS

Name:	Dimethyl 3-Methyl-Trans-1 2-Cyclopropanedicarboxylate 99% Material Safety Data Sheet
Synonym:	None known
CAS:	28363-79-3

Section 1 - Chemical Product MSDS Name:Dimethyl 3-Methyl-Trans-1 2-Cyclopropanedicarboxylate 99% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
28363-79-3	Dimethyl 3-Methyl-Trans-1,2-Cyclopropa	99	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Containers may explode when heated.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Cool containers with flooding quantities of water until well after fire is out. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Avoid runoff into storm sewers and ditches which lead to waterways.
Clean up spills immediately, observing precautions in the Protective Equipment section. Absorb spill using an absorbent, non-combustible material such as earth, sand, or vermiculite. Do not use combustible materials such as sawdust. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 28363-79-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear, colorless
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 100 deg C @ 18.00mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H12O4
Molecular Weight: 172.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 28363-79-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Dimethyl 3-Methyl-Trans-1,2-Cyclopropanedicarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 28363-79-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 28363-79-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 28363-79-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基-反-1,2-环丙烷二羧酸甲酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以93%的产率得到(1R,2R)-3-methylcyclopropane-1,2-dicarbohydrazide
  参考文献：
  名称：

  Saal, Wolfgang von der; Reinhardt, Robert; Seidenspinner, Hubert-Matthias, Liebigs Annalen der Chemie, 1989, p. 703 - 712

  摘要：

  DOI：
• 作为产物：
  描述：

  4,6-二甲基-2-氧-2H-吡喃-5-甲酸乙酯 在 硫酸 、 水 、 溴 、 氧气 、 一水合肼 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 氯仿 、 乙腈 为溶剂， 反应 72.33h， 生成 3-甲基-反-1,2-环丙烷二羧酸甲酯
  参考文献：
  名称：

  化合物、聚合物、液晶取向剂、液晶取向膜、液晶显示元件、以及制造方法

  摘要：

  提供一种化合物、聚合物、液晶取向剂、液晶取向膜、液晶显示元件、以及制造方法。一种二胺化合物，由下述通式(1)表示。进而一种液晶取向剂，含有聚合物，所述聚合物是使包含含有所述二胺化合物的二胺类与四羧酸二酐类的原料组合物聚合而成。通式(1)中，R1及R2各自独立地表示氢原子、卤素原子、碳数1至6的烷基、碳数1至6的卤代烷基或碳数1至6的烷氧基。R1与R2可成为一体而形成可经取代的亚甲基。X各自独立地表示卤素原子、碳数1至6的烷基、碳数1至6的卤代烷基或碳数1至6的烷氧基，n表示0至4的整数。

  公开号：

  CN113717062A

文献信息

• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：CHDI FOUNDATION INC

  公开号：WO2013151707A1

  公开（公告）日：2013-10-10

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising the same and methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof described herein, effective to reduce signs or symptoms of the disease or disorder. These diseases include neurodegenerative disorders such as Huntington's disease.

  本文描述了某些化合物，或其药学上可接受的盐或前药、含有这些化合物的药物组合物以及治疗对抑制KMO活性有反应的某些疾病和障碍患者的方法，这些方法包括向此类患者施用至少一种本文所述的化合物，或其药学上可接受的盐或前药的有效量，以减轻疾病或障碍的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。
• Cyclopropanation of Dimethyl Fumarate and Maleate with<i>gem</i>-Dihalides Catalyzed by Co(0)- or Ni(0)-Complex and Zinc
  作者：Hiroyoshi Kanai、Yoshimasa Nishiguchi、Hideki Matsuda

  DOI：10.1246/bcsj.56.1592

  日期：1983.6

  The reaction of bis(acetonitrile)bis(diethyl fumarate)cobalt(0) with dibromomethane gave diethyl trans-1,2-cyclopropanedicarboxylate in a 67% yield based on the cobalt complex. Dimethyl cis-1,2-cyclopropanedicarboxylate was obtained in a 52% yield from the reaction of dimethyl maleate with dibromomethane in the presence of acetonitrilebis(dimethyl maleate)nickel(0) accompanied by the formation of the

  双(乙腈)双(富马酸二乙酯)钴(0)与二溴甲烷的反应得到反式-1,2-环丙烷二羧酸二乙酯，产率为67%，基于钴配合物。在乙腈双（马来酸二甲酯）镍 (0) 存在下，马来酸二甲酯与二溴甲烷反应，同时以 14% 的产率形成反式异构体，以 52% 的产率获得顺式-1,2-环丙烷二甲酸二甲酯. 添加锌以基于钴或镍的超过 100% 的产率得到环丙烷。3-甲基-和3,3-二甲基-1,2-环丙烷二甲酸酯是通过富马酸或马来酸二甲酯与1,1-二溴乙烷和2,2-二溴丙烷反应制备的。钴催化剂体系的产率随着墒二溴化物取代基的增加而降低，而在镍催化剂体系中的变化并不明显。少量异丙烯基琥珀酸二甲酯作为 2,2-二溴丙烷反应的副产物形成。简要讨论了一种机制，它...
• Cyclopropane formation by nickel-catalysed electroreductive coupling of activated olefins and unactivated gem-dibromo compounds
  作者：Stéphane Sengmany、Eric Léonel、Jean Paul Paugam、Jean-Yves Nédélec

  DOI：10.1016/s0040-4020(01)01133-4

  日期：2002.1

  Cyclopropyl derivatives have been prepared with good yields by transition-metal catalysed electroreductive coupling of activated olefins and unactivated gem-dibromo compounds. This electrolysis is characterized by the use of a Fe/Ni catalyst system, acetonitrile as the solvent and a catalytic amount of triphenylphosphine as ligand. This procedure is a good alternative to the classical preparations

  通过过渡金属催化的活化烯烃和未活化的宝石-二溴化合物的电还原偶联，已经以良好的收率制备了环丙基衍生物。该电解的特征在于使用Fe / Ni催化剂体系，乙腈作为溶剂，催化量的三苯基膦作为配体。该方法是从活化烯烃经典制备环丙基衍生物的一个很好的选择（Simmons-Smith反应，重氮甲烷的1,3-偶极加成，磷和硫的硫化物的1,4-加成）。
• Cyclopropane formation by electroreductive coupling of activated olefins and gem-polyhalo compounds
  作者：Eric Léonel、Jean Paul Paugam、Sylvie Condon-Gueugnot、Jean-Yves Nédélec

  DOI：10.1016/s0040-4020(98)00059-3

  日期：1998.3

  be involved to lead to the products. The radical anion of the olefin can react with the halo compound by electron-tranfer followed by radical coupling, or be reduced into the dianion which reacts by nucleophilic displacement.

  通过活化烯烃与宝石-多卤代化合物的电还原偶联，已经以令人满意的产率制备了环丙基衍生物。当烯烃比有机卤化物更容易还原时，该反应是有效的。可以涉及两种类型的中间体来产生产物。烯烃的自由基阴离子可通过电子转移与自由基偶联而与卤代化合物反应，或可通过亲核取代反应还原为二价阴离子。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20050107389A1

  公开（公告）日：2005-05-19

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其表现出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物作为多巴胺D3受体成像剂的方法。